Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis

ENNIO GIULIO FAVALLI, ELENA AGAPE and ROBERTO CAPORALI
The Journal of Rheumatology August 2020, 47 (8) 1296; DOI: https://doi.org/10.3899/jrheum.200507
ENNIO GIULIO FAVALLI
Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for ENNIO GIULIO FAVALLI
  • For correspondence: enniofavalli@me.com
ELENA AGAPE
Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERTO CAPORALI
Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, and Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

The outbreak of COVID-19 in December 2019 in China has very quickly become a global health emergency, with almost 2 million infected patients worldwide1. Along with the spread of the pandemic, there has been growing concern about the management of fragile patients with rheumatic conditions. There are still very few data available on this aspect. In particular, subjects affected by connective tissue diseases (CTD) are known to have an increased infectious risk compared to the healthy population because of a general impairment of the immune system intrinsic to the autoimmune disease itself, the iatrogenic effect linked to the use of immunosuppressive drugs, and the high number of comorbidities that often complicate the clinical picture2,3. On the other hand, the progressive increase in the knowledge about the pathogenesis of the infection is paving the way for the use of certain drugs common in rheumatology to also treat COVID-194.

As rheumatologists operating in one of the major epicenters of the pandemic (Milan, Italy), we conducted a survey to investigate the effect of COVID-19 on patients with CTD followed at the Research Center for Adult and Pediatric Rheumatic Diseases of the ASST Gaetano Pini-CTO. The survey included demographics, clinical information on the rheumatic disease, the incidence of COVID-19 confirmed by nasopharyngeal swab, the frequency of respiratory symptoms of suspected viral infections, and how the outbreak affected the patient’s behavior and the course of CTD. In the period between February 25 and March 25, 2020, the survey was administered face-to-face to patients who were assessed in the outpatient CTD clinic of our center or by telephone to those who missed an appointment scheduled for the same period.

The overall study population included 123 adult patients (110 females) with systemic lupus erythematosus (n = 61), systemic sclerosis (SSc; n = 43), undifferentiated CTD (n = 9), or Sjögren syndrome (n = 10). The mean age (± SD) was 49.3 (14.4) years and the mean disease duration 10.2 (8.7) years. About 60% of patients were treated with conventional synthetic disease-modifying drugs [31 hydroxychloroquine (HCQ), 22 mycophenolate, 11 methotrexate, 8 azathioprine, and 1 cyclosporine], 25 patients were receiving biological agents [18 belimumab, 5 rituximab (RTX), and 2 tocilizumab (TCZ)], and 64.2% were also taking corticosteroids (mean dose 5.3 mg daily). The only recorded patient with a COVID-19 positive swab was a 32-year-old woman with SSc and pulmonary involvement treated with HCQ and RTX. She developed a severe pattern of COVID-19 interstitial pneumonia requiring hospitalization in intensive care, where, despite intubation and treatment with TCZ, the patient died. In the same period of observation, the incidence of COVID-19 positivity in our region (Lombardy) was consistent with what we observed in our cohort (0.62 vs 0.81%, respectively)5. A further 14 patients reported respiratory symptoms consistent with a viral infection, but they did not have access to the swab. In these patients we observed a mild clinical course of infectious disease with a rapid resolution of symptoms. They did not require the discontinuation of ongoing rheumatological therapy and did not experience a CTD relapse. Among the latter group, 44.4% were taking HCQ therapy versus 24.2% of patients who did not develop respiratory symptoms. These data were not consistent with the proposed protective effect of the drug against COVID-19 infection6. However, it is important to point out that to date, preliminary data have demonstrated the efficacy of antimalarials in the treatment of COVID-197, while at the moment no evidence is yet available about their potential prophylactic effect in the prevention of contagion8.

Overall, of 123 patients, only 5 have discontinued their current rheumatological therapy (2 for fear of contagion and 3 upon indication of a non-rheumatologist consultant) and 115 have maintained stable disease activity without experiencing flares.

The vast majority of the study population (84.1%) reported to have adopted specific precautions to prevent the contagion such as social distancing (55.2%), use of masks (58.1%), and non-working or home-working (60.1% of workers) since the outbreak began. This positive propensity is likely to depend on the very fact of being carriers of a disease with increased infection risk and should certainly be taken into account when assessing the overall incidence of COVID-19 in the cohort of patients with CTD compared with the general population.

These preliminary data seem to suggest that our approach of encouraging patients with CTD to maintain ongoing rheumatological therapy and to adhere strictly to the norms to avoid infection has prevented rheumatic disease relapse without increasing the risk of COVID-19. While waiting for our results to be confirmed on larger samples, this information can certainly be useful to all rheumatologists worldwide facing the pandemic.

Footnotes

  • The current analysis is part of a project to collect observational data from rheumatological patients followed at the ASST Gaetano Pini-CTO.

  • The project was approved by the Ethics Committee of the Gaetano Pini Institute with approval number 141/2010. All included patients signed informed consent to participate in the data collection.

REFERENCES

  1. 1.↵
    1. Huang C,
    2. Wang Y,
    3. Li X,
    4. Ren L,
    5. Zhao J,
    6. Hu Y,
    7. et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Goldblatt F,
    2. Chambers S,
    3. Rahman A,
    4. Isenberg D
    . Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009;18:682–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Alarcón GS
    . Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin N Am 2006;20:849–75.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Favalli EG,
    2. Ingegnoli F,
    3. Lucia OD,
    4. Cincinelli G,
    5. Cimaz R,
    6. Caporali R
    . COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020;19:102523.
    OpenUrl
  5. 5.↵
    Lombardy region Web site. [Internet. Accessed April 24, 2020.] Available from: www.regione.lombardia.it/wps/portal/istituzionale
  6. 6.↵
    1. Touret F,
    2. de Lamballerie X
    . Of chloroquine and COVID-19. Antivir Res 2020;177:104762.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Gao J,
    2. Tian Z,
    3. Yang X
    . Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;2020:01047.
    OpenUrl
  8. 8.↵
    1. Spinelli FR,
    2. Ceccarelli F,
    3. Franco MD,
    4. Conti F
    . To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann Rheum Dis 2020;79:666–7.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 8
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
ENNIO GIULIO FAVALLI, ELENA AGAPE, ROBERTO CAPORALI
The Journal of Rheumatology Aug 2020, 47 (8) 1296; DOI: 10.3899/jrheum.200507

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis
ENNIO GIULIO FAVALLI, ELENA AGAPE, ROBERTO CAPORALI
The Journal of Rheumatology Aug 2020, 47 (8) 1296; DOI: 10.3899/jrheum.200507
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Rapidly Progressive Systemic Sclerosis–associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guérin Therapy for Early-stage Bladder Cancer
  • Axial Involvement in Psoriatic Arthritis: Effect on Peripheral Arthritis and Differential Features With Axial Spondyloarthritis in South America
  • The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire